Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obesity | 12 | 2019 | 1176 | 1.480 |
Why?
|
| Exercise | 13 | 2019 | 673 | 1.250 |
Why?
|
| Caloric Restriction | 4 | 2019 | 106 | 1.120 |
Why?
|
| Aging | 6 | 2017 | 946 | 0.970 |
Why?
|
| Aged | 32 | 2020 | 10314 | 0.910 |
Why?
|
| Pericardium | 2 | 2011 | 52 | 0.760 |
Why?
|
| Adipose Tissue | 4 | 2011 | 349 | 0.760 |
Why?
|
| Resistance Training | 3 | 2016 | 82 | 0.730 |
Why?
|
| Dietary Proteins | 1 | 2020 | 55 | 0.720 |
Why?
|
| Exercise Therapy | 5 | 2019 | 270 | 0.720 |
Why?
|
| Inflammation Mediators | 2 | 2012 | 104 | 0.700 |
Why?
|
| Abdominal Fat | 3 | 2018 | 50 | 0.640 |
Why?
|
| Body Composition | 6 | 2019 | 397 | 0.630 |
Why?
|
| Neural Cell Adhesion Molecule L1 | 1 | 2018 | 2 | 0.630 |
Why?
|
| Scavenger Receptors, Class E | 2 | 2008 | 2 | 0.630 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2018 | 37 | 0.620 |
Why?
|
| Life Style | 3 | 2018 | 408 | 0.610 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 45 | 0.610 |
Why?
|
| Exosomes | 1 | 2018 | 43 | 0.590 |
Why?
|
| Postmenopause | 2 | 2011 | 430 | 0.590 |
Why?
|
| Geriatrics | 1 | 2018 | 85 | 0.580 |
Why?
|
| Female | 31 | 2020 | 20015 | 0.580 |
Why?
|
| Inflammation | 3 | 2010 | 530 | 0.580 |
Why?
|
| Adiposity | 4 | 2016 | 198 | 0.570 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2018 | 120 | 0.560 |
Why?
|
| Male | 29 | 2020 | 19217 | 0.540 |
Why?
|
| Humans | 36 | 2020 | 32114 | 0.540 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2011 | 1062 | 0.520 |
Why?
|
| Vascular Diseases | 1 | 2015 | 66 | 0.490 |
Why?
|
| Alzheimer Disease | 1 | 2018 | 327 | 0.480 |
Why?
|
| Neurons | 1 | 2018 | 410 | 0.480 |
Why?
|
| Hypertension | 5 | 2017 | 960 | 0.450 |
Why?
|
| Electrocardiography | 1 | 2018 | 605 | 0.440 |
Why?
|
| Coronary Circulation | 2 | 2016 | 43 | 0.420 |
Why?
|
| Middle Aged | 17 | 2019 | 11839 | 0.420 |
Why?
|
| Physical Fitness | 3 | 2010 | 131 | 0.410 |
Why?
|
| Myocardium | 2 | 2016 | 186 | 0.400 |
Why?
|
| Lipoprotein Lipase | 1 | 2011 | 14 | 0.400 |
Why?
|
| Lipoproteins, VLDL | 1 | 2011 | 27 | 0.390 |
Why?
|
| Lipase | 1 | 2011 | 28 | 0.390 |
Why?
|
| Atherosclerosis | 3 | 2015 | 766 | 0.390 |
Why?
|
| C-Reactive Protein | 4 | 2017 | 238 | 0.370 |
Why?
|
| Brain | 1 | 2018 | 951 | 0.370 |
Why?
|
| Aged, 80 and over | 10 | 2017 | 3990 | 0.370 |
Why?
|
| Body Mass Index | 6 | 2019 | 923 | 0.360 |
Why?
|
| Blood Pressure | 3 | 2015 | 845 | 0.360 |
Why?
|
| Exercise Tolerance | 4 | 2019 | 125 | 0.360 |
Why?
|
| Ginkgo biloba | 1 | 2010 | 19 | 0.350 |
Why?
|
| Nitric Oxide | 2 | 2009 | 111 | 0.350 |
Why?
|
| Nitrites | 1 | 2009 | 21 | 0.350 |
Why?
|
| Nitrates | 1 | 2009 | 27 | 0.340 |
Why?
|
| Plant Extracts | 1 | 2010 | 61 | 0.340 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 251 | 0.330 |
Why?
|
| Lipoproteins, LDL | 1 | 2009 | 81 | 0.320 |
Why?
|
| Aorta | 1 | 2009 | 126 | 0.310 |
Why?
|
| Comorbidity | 1 | 2009 | 566 | 0.290 |
Why?
|
| Logistic Models | 3 | 2018 | 783 | 0.270 |
Why?
|
| Heart Failure | 3 | 2018 | 639 | 0.260 |
Why?
|
| Interleukin-6 | 3 | 2012 | 247 | 0.240 |
Why?
|
| Sex Factors | 2 | 2017 | 667 | 0.240 |
Why?
|
| Exercise Test | 4 | 2019 | 227 | 0.230 |
Why?
|
| Age Factors | 3 | 2018 | 1189 | 0.200 |
Why?
|
| Gait | 3 | 2017 | 142 | 0.190 |
Why?
|
| Oxygen Consumption | 4 | 2019 | 154 | 0.190 |
Why?
|
| Polymorphism, Genetic | 2 | 2014 | 184 | 0.190 |
Why?
|
| Cardiovascular Diseases | 3 | 2017 | 1128 | 0.180 |
Why?
|
| Hand Strength | 2 | 2012 | 101 | 0.180 |
Why?
|
| North Carolina | 3 | 2015 | 1538 | 0.180 |
Why?
|
| Weight Loss | 2 | 2015 | 480 | 0.170 |
Why?
|
| Proteins | 1 | 2020 | 144 | 0.170 |
Why?
|
| Chronic Disease | 3 | 2010 | 406 | 0.170 |
Why?
|
| Intra-Abdominal Fat | 3 | 2018 | 63 | 0.170 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 684 | 0.160 |
Why?
|
| Sepharose | 1 | 2018 | 6 | 0.160 |
Why?
|
| Biotinylation | 1 | 2018 | 10 | 0.160 |
Why?
|
| Body Fat Distribution | 1 | 2018 | 34 | 0.160 |
Why?
|
| Mobility Limitation | 3 | 2014 | 219 | 0.160 |
Why?
|
| Risk Factors | 7 | 2017 | 3880 | 0.150 |
Why?
|
| Research | 1 | 2018 | 74 | 0.150 |
Why?
|
| Protein Binding | 1 | 2018 | 201 | 0.150 |
Why?
|
| Cell Separation | 1 | 2018 | 92 | 0.150 |
Why?
|
| Treatment Outcome | 3 | 2019 | 3306 | 0.150 |
Why?
|
| Geriatric Assessment | 4 | 2016 | 390 | 0.150 |
Why?
|
| Bacterial Proteins | 1 | 2018 | 90 | 0.150 |
Why?
|
| Disability Evaluation | 2 | 2019 | 240 | 0.150 |
Why?
|
| Avitaminosis | 1 | 2017 | 2 | 0.150 |
Why?
|
| Time Factors | 2 | 2015 | 2151 | 0.150 |
Why?
|
| Vitamin K 1 | 1 | 2017 | 11 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2018 | 1328 | 0.140 |
Why?
|
| Lysine | 1 | 2017 | 23 | 0.140 |
Why?
|
| Heart | 1 | 2018 | 177 | 0.140 |
Why?
|
| Gene Expression | 1 | 2018 | 338 | 0.140 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2016 | 27 | 0.130 |
Why?
|
| Elasticity | 1 | 2015 | 36 | 0.130 |
Why?
|
| African Continental Ancestry Group | 1 | 2017 | 363 | 0.130 |
Why?
|
| Dobutamine | 1 | 2016 | 69 | 0.130 |
Why?
|
| Ankle Brachial Index | 1 | 2015 | 39 | 0.130 |
Why?
|
| Waist Circumference | 1 | 2015 | 90 | 0.130 |
Why?
|
| Continental Population Groups | 1 | 2017 | 237 | 0.130 |
Why?
|
| Stroke Volume | 1 | 2018 | 348 | 0.130 |
Why?
|
| European Continental Ancestry Group | 2 | 2017 | 1166 | 0.120 |
Why?
|
| Heart Ventricles | 1 | 2016 | 135 | 0.120 |
Why?
|
| Forecasting | 1 | 2015 | 143 | 0.120 |
Why?
|
| Heart Rate | 1 | 2017 | 335 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2017 | 180 | 0.120 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2014 | 35 | 0.120 |
Why?
|
| Forced Expiratory Volume | 1 | 2014 | 87 | 0.120 |
Why?
|
| Single-Blind Method | 2 | 2012 | 203 | 0.120 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 519 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 560 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2015 | 548 | 0.110 |
Why?
|
| Triglycerides | 2 | 2011 | 230 | 0.110 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2014 | 132 | 0.110 |
Why?
|
| Activities of Daily Living | 2 | 2014 | 257 | 0.100 |
Why?
|
| Gene Frequency | 2 | 2014 | 220 | 0.100 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2012 | 9 | 0.100 |
Why?
|
| Factor Analysis, Statistical | 1 | 2012 | 77 | 0.100 |
Why?
|
| Perfusion | 1 | 2011 | 73 | 0.100 |
Why?
|
| DNA Primers | 1 | 2011 | 91 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2018 | 898 | 0.100 |
Why?
|
| Linear Models | 2 | 2010 | 449 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 146 | 0.100 |
Why?
|
| Base Sequence | 1 | 2011 | 252 | 0.090 |
Why?
|
| Genotype | 2 | 2014 | 733 | 0.090 |
Why?
|
| Hemodynamics | 1 | 2011 | 155 | 0.090 |
Why?
|
| Aorta, Thoracic | 1 | 2011 | 85 | 0.090 |
Why?
|
| Aortic Diseases | 1 | 2011 | 63 | 0.090 |
Why?
|
| Oxidative Stress | 2 | 2009 | 231 | 0.090 |
Why?
|
| Coronary Disease | 1 | 2011 | 211 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2015 | 2283 | 0.090 |
Why?
|
| Plethysmography | 1 | 2009 | 15 | 0.090 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2009 | 10 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2015 | 1429 | 0.080 |
Why?
|
| Multienzyme Complexes | 1 | 2009 | 18 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 1428 | 0.080 |
Why?
|
| Blood Flow Velocity | 1 | 2009 | 77 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 2265 | 0.080 |
Why?
|
| Probability | 1 | 2009 | 159 | 0.080 |
Why?
|
| Absorptiometry, Photon | 2 | 2019 | 143 | 0.080 |
Why?
|
| Double-Blind Method | 1 | 2010 | 525 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2010 | 185 | 0.080 |
Why?
|
| Exons | 1 | 2008 | 52 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2011 | 1817 | 0.080 |
Why?
|
| Thinness | 1 | 2008 | 33 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 218 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 210 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2008 | 96 | 0.070 |
Why?
|
| Lipids | 1 | 2009 | 232 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 582 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 145 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 1542 | 0.070 |
Why?
|
| Incidence | 1 | 2010 | 1199 | 0.070 |
Why?
|
| Kidney | 1 | 2010 | 518 | 0.070 |
Why?
|
| Body Weight | 1 | 2008 | 310 | 0.070 |
Why?
|
| Overweight | 1 | 2008 | 280 | 0.070 |
Why?
|
| Subcutaneous Fat, Abdominal | 2 | 2018 | 15 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2016 | 3510 | 0.060 |
Why?
|
| Adult | 2 | 2011 | 9380 | 0.050 |
Why?
|
| Antihypertensive Agents | 2 | 2017 | 352 | 0.050 |
Why?
|
| Health Education | 2 | 2014 | 163 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2019 | 100 | 0.040 |
Why?
|
| Executive Function | 1 | 2019 | 57 | 0.040 |
Why?
|
| Fatigue | 1 | 2019 | 85 | 0.040 |
Why?
|
| Thigh | 1 | 2018 | 42 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 371 | 0.040 |
Why?
|
| Muscle Strength | 1 | 2018 | 161 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 45 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2017 | 45 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2019 | 494 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 107 | 0.030 |
Why?
|
| Calcinosis | 1 | 2017 | 146 | 0.030 |
Why?
|
| Echocardiography, Stress | 1 | 2016 | 27 | 0.030 |
Why?
|
| Coronary Stenosis | 1 | 2016 | 30 | 0.030 |
Why?
|
| Microcirculation | 1 | 2016 | 65 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2016 | 55 | 0.030 |
Why?
|
| Cognition | 1 | 2019 | 556 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 753 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2016 | 156 | 0.030 |
Why?
|
| Spirometry | 1 | 2014 | 27 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 226 | 0.030 |
Why?
|
| Brachial Artery | 1 | 2014 | 69 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2017 | 475 | 0.030 |
Why?
|
| Stroke | 1 | 2017 | 585 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 77 | 0.020 |
Why?
|
| Dinoprost | 1 | 2009 | 10 | 0.020 |
Why?
|
| Nitrogen Oxides | 1 | 2009 | 5 | 0.020 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2009 | 28 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2009 | 43 | 0.020 |
Why?
|
| Antioxidants | 1 | 2009 | 115 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 464 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2009 | 173 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 510 | 0.020 |
Why?
|
| United States | 1 | 2015 | 3976 | 0.020 |
Why?
|
| Health Status | 1 | 2008 | 400 | 0.020 |
Why?
|
| Animals | 1 | 2010 | 7542 | 0.010 |
Why?
|